[ad_1]
With a market cap of $189.6 billion, Abbott Laboratories (ABT) is a world healthcare firm that discovers, develops, manufactures, and sells a variety of medical merchandise throughout prescribed drugs, diagnostics, vitamin, and medical gadgets. It serves sufferers worldwide with options spanning illness remedy, testing and diagnostics, vitamin, cardiovascular care, diabetes administration, and neuromodulation.
Shares of the Abbott Park, Illinois-based firm have underperformed the broader market over the previous 52 weeks. ABT inventory has decreased 15.1% over this timeframe, whereas the broader S&P 500 Index ($SPX) has gained 15.4%. Furthermore, the inventory has declined practically 13% on a YTD foundation, in comparison with SPX’s 1.1% rise.
Trying nearer, shares of the maker of toddler components, medical gadgets and medicines have additionally lagged behind the State Road Well being Care Choose Sector SPDR ETF’s (XLV) 5.9% return over the previous 52 weeks.
Abbott shares tumbled 10% on Jan. 22 after the corporate reported This autumn 2025 income of $11.46 billion, lacking Wall Road estimates regardless of adjusted EPS of $1.50 assembly expectations. Traders have been involved by weak efficiency in key segments, significantly Diet, the place This autumn gross sales fell 8.9% reported (9.1% natural), and Diagnostics, which declined 2.5% reported, reflecting decrease volumes and fading COVID-19 testing demand. The selloff was amplified by Abbott’s 2026 natural gross sales progress outlook of 6.5% – 7.5%, which got here in under prior consensus.
For the fiscal yr ending in December 2026, analysts count on ABT’s adjusted EPS to develop 10.3% year-over-year to $5.68. The corporate’s earnings shock historical past is promising. It topped or met the consensus estimates within the final 4 quarters.
Among the many 28 analysts protecting the inventory, the consensus ranking is a “Sturdy Purchase.” That’s primarily based on 20 “Sturdy Purchase” rankings, two “Reasonable Buys,” and 6 “Holds.”
On Jan. 23, Wells Fargo analyst Larry Biegelsen lowered Abbott’s value goal to $122 and maintained an “Chubby” ranking.
The imply value goal of $134.38 represents a premium of 23.3% to ABT’s present value. The Road-high value goal of $158 suggests a 44.9% potential upside.
On the date of publication, Sohini Mondal didn’t have (both instantly or not directly) positions in any of the securities talked about on this article. All info and information on this article is solely for informational functions. This text was initially revealed on Barchart.com
[ad_2]
